Phlebotomy Recommendations for Polycythemia

Polycythemia Vera (PV)

The National Comprehensive Cancer Network recommends maintaining hematocrit strictly below 45% for all PV patients regardless of risk category 3, 4
Consider lower targets (approximately 42%) for women and African Americans due to physiological differences in hematocrit values, as suggested by the Mayo Clinic 1
Maintaining hematocrit <45% significantly reduces thrombotic complications compared to higher targets, according to the CYTO-PV study 4
For low-risk PV, phlebotomy (to maintain hematocrit <45%) plus low-dose aspirin (81-100 mg/day) is recommended, while cytoreductive therapy is not recommended as initial treatment, as per the National Comprehensive Cancer Network 3, 4
For high-risk PV, phlebotomy (to maintain hematocrit <45%) plus low-dose aspirin (81-100 mg/day) and cytoreductive therapy (hydroxyurea or interferons) is recommended, as per the National Comprehensive Cancer Network 3, 4

Phlebotomy should be considered when hematocrit exceeds 52-55%, which is a higher threshold than for PV, according to Praxis Medical Insights 2

Phlebotomy should be performed under careful conditions with appropriate fluid replacement to avoid hypotension or fluid overload, as recommended by the Mayo Clinic 1
Monitor hematocrit levels regularly to maintain target values, as suggested by the National Comprehensive Cancer Network 4

Phlebotomy reduces risk of thrombotic complications, as reported by the Mayo Clinic 1
Phlebotomy extends survival in PV patients when combined with modern supportive care, according to the Mayo Clinic 1